Dr. Simon on Durvalumab for Patients With Lung Cancer
George R. Simon, MD, FACP, FCCP
George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.
Durvalumab, a PD-L1 inhibitor, recently demonstrated improved progression-free survival after patients with stage III non-small cell lung cancer (NSCLC) received definitive concurrent chemotherapy and radiation therapy in the PACIFIC trial. Durvalumab is currently in the process of getting FDA approval, says Simon.
The combination of pembrolizumab (Keytruda) with carboplatin and pemetrexed in the first-line setting for NSCLC has already been approved. The CheckMate 227 trial is currently investigating the combination of durvalumab and the CTLA-4 inhibitor ipilimumab (Yervoy) in multiple diseases, explains Simon.